Sarepta reports Q3 EPS 62c, consensus (13c)
The Fly

Sarepta reports Q3 EPS 62c, consensus (13c)

Reports Q3 revenue $429.8M, consensus $409.3M. “I am pleased to report another strong quarter of performance, as we posted $429.8 million in net product revenue for the third quarter, a 39% increase over the same quarter of the prior year. Reflecting our detailed preparation and track record of commercial execution, the launch of ELEVIDYS is proceeding to plan. ELEVIDYS net product revenue was $181.0 million in the quarter, exceeding prior guidance. If one includes royalty revenue generated on Roche’s ex-US sales of ELEVIDYS, total ELEVIDYS performance was $190.5 million for the quarter. Likewise, net product revenue for our three PMOs — EXONDYS 51, VYONDYS 53, and AMONDYS 45 – performed well, achieving approximately $248.8 million in the quarter and, as anticipated, reflecting a lack of near-term cannibalization from the launch of ELEVIDYS,” said Doug Ingram, president and CEO, Sarepta (SRPT) Therapeutics. “At the same time, we have made important decisions regarding portfolio prioritization and have made great progress on our pipeline in the quarter. As examples, by mid-2025 we will have submitted a Biologics License Application for one and will be in clinical trials for two others of our Limb-girdle muscular dystrophy programs. Assuming success, these three therapeutic candidates will deliver our next wave of approved therapies as our multi-program platform advances productively.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App